NCT00337883View on ClinicalTrials.gov

A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

October 31, 2005

Conditions
Glioblastoma
Interventions
DRUG

Erlotinib HCl (OSI-774)

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY